Nanotherapy based on magneto‐mechanochemical modulation of tumor redox state

Abstract

Magnetic nanoparticles (MNs) are typically used as contrast agents for magnetic resonance imaging or as drug carriers with a remotely controlled delivery to the tumor. However, they can also potentiate the action of anticancer drugs under the influence of applied constant magnetic (CMFs) and electromagnetic fields (EMFs). This review demonstrates the role of magneto‐mechanochemical effects produced by MNs alone and loaded with anticancer agents (MNCs) in response to CMFs and EMFs for modulation of tumor redox state. The combined treatment is suggested to act by two mechanisms: spin‐dependent electron transport propagates free radical chain reactions, while magnetomechanical interactions cause conformational changes in drug molecules loaded onto MNs and generate reactive oxygen species (ROS). By adjusting the parameters of CMFs and EMFs during the magneto‐mechanochemical synthesis and subsequent treatment, it is possible to modulate ROS production and switch redox signaling involved in ERK1/2 and NF‐κB pathways from initiation of tumor growth to inhibition. Observations of tumor volume in different animal models and treatment combinations reported a 6%–70% reduction as compared with conventional drugs. Despite these results, there is a general lack of research in magnetic nanotheranostics that link redox changes across multiple levels of organization in the tumor‐bearing host. Further multidisciplinary studies with more focus on the relationship between the electron transport processes in biomolecules and their effects on the tumor‐host interaction should accelerate the clinical translation of magnetic nanotheranostics. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies Nanotechnology Approaches to Biology > Nanoscale Systems in Biology

The Emerging Role of Metformin in the Treatment of Hepatocellular Carcinoma: Is There Any Value in Repurposing Metformin for HCC Immunotherapy?

“…While mounting evidence suggests that metformin might enhance the activity of immune cells, more research is needed to shed light into the exact mechanisms by which metformin might enhance immunotherapy in HCC. In the era of personalized medicine and cutting-edge individualized nanotherapy [ 152 ], the concept of repurposing a drug from the World Health Organization’s list of essential medicines to enhance immunotherapy responses can be likened to discovering the “Achilles heel” of HCC. Repurposing drugs may provide a cost-effective and expedient alternative to developing new therapeutics [ 148 ].…”

Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications

“…The lack of well-designed clinical trials exploring EPH/ephrin-targeted therapies hinders the assessment of their efficacy and safety in HCC and CCA patients. Future research efforts should address these limitations to fully evaluate the potential of targeting EPH/ephrin as a therapeutic strategy for HCC and CCA patients [ 137 ].…”

Unveiling the Yin-Yang Balance of M1 and M2 Macrophages in Hepatocellular Carcinoma: Role of Exosomes in Tumor Microenvironment and Immune Modulation

“…Furthermore, nanotheranostics can be designed to selectively accumulate in HCC cells or the tumor microenvironment, allowing for targeted delivery of therapeutic agents, such as chemotherapy drugs or gene therapies, directly to the tumor site while minimizing off-target effects [ 150 ]. Additionally, nanotheranostics can be tailored to respond to specific tumor characteristics or stimuli, such as pH, temperature, or enzymatic activity, enabling controlled release of therapeutics within the ΤΜΕ [ 151 , 152 ]. Overall, nanotheranostics holds great promise in advancing the field of HCC treatment by combining diagnostics and therapeutics into a single nanoscale platform for enhanced precision, efficacy, and personalized care.…”